ASH - Oncology

Videos

Rami Komrokji, MD, discusses what the MOST study's results mean for investigating second-line treatment options in myelofibrosis. 

Investigating Second-Line Treatment Options for Myelofibrosis

Articles

CAR T-cell therapy associated with greater anti-cancer activity in treating multiple myeloma. 

ALLO-715 Found to Be Effective Against Multiple Myeloma

Rami Komrokji, MD, discusses whether the majority of patients in the MOST study were being treated at the time of enrollment, and why real-world data is so essential.

Collecting Real-World Data from Patients With Myelofibrosis Is Essential

Rami Komrokji, MD, discusses common prior treatments of low-risk and intermediate-1 risk patients in the MOST study. 

Common Prior Treatments of Participants in the MOST Study

Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about why data are limited in myelofibrosis.

Obtaining Real-World Disease, Demographic Data on Myelofibrosis

For patients with relapsed/refractory multiple myeloma (RRMM), teclistamab was found to have a manageable safety profile, according to data presented at the virtual American Society of Hematology conference.

Updated Phase 1 Results of Treatment With Teclistamab for Patients With Relapsed/Refractory Multiple Myeloma

Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about factors in treatment decisions for patients with myelofibrosis.

Making Treatment Decisions for Patients with Myelofibrosis

Data from a preliminary phase 1b/2 study demonstrated a single low-dose infusion of ciltacabtagene autoleucel resulted in early, deep, and durable responses in heavily pretreated patients with multiple myeloma.

Preliminary Results of Ciltacabtagene Autoleucel in Treating Relapsed/Refractory Multiple Myeloma

MEDI2228, an ADC that targets the extracellular domain of human BCMA, demonstrated clinical efficacy at all dose levels in treating patients with relapsed/refractory multiple myeloma.

The Clinical Efficacy of MEDI2228 in Treating Relapsed/Refractory Multiple Myeloma

Trials confirm patients with chronic lymphocytic leukemia treated with venetoclax-based regimens achieve higher rates of undetectable minimal residual disease, which may be associated with a lower risk of future disease progression or death.